## AMENDMENTS TO THE CLAIMS

**Listing of Claims**

The following listing of claims replaces all prior versions and listings of claims in the application.

1. (Original): A protein consisting of an amino acid sequence represented by SEQ ID NO:1, or a salt thereof.

2. (Original): A protein having an amino acid sequence derived from an amino acid sequence represented by SEQ ID NO: 2 by deletion of 0 to 10 amino acid residues from the N-terminal and deletion of 0 to 10 amino acid residues from the C-terminal and having 120 to 139 amino acid residues, or a salt thereof.

3. (Original): A protein consisting of an amino acid sequence derived from an amino acid sequence of a protein represented by SEQ ID NO: 1 or 2 and having deletion, substitution or addition of one or several amino acids and having a function substantially identical with that of the protein according to claim 1 or 2, or a salt thereof.

4. (Currently amended): A polynucleotide containing a polynucleotide encoding the amino acid sequence of a protein according to ~~any one of claims 1 to 3~~ claim 1 or 2.

5. (Original): The polynucleotide according to claim 4, containing a nucleotide sequence represented by SEQ ID NO: 3 or 4.

6. (Currently amended): An expression system containing a polynucleotide according to claim 4 [[or 5]].

7. (Currently amended): A recombinant vector containing a polynucleotide according to claim 4 [[or 5]].

8. (Currently amended): A transformant which is transformed with a polynucleotide according to claim 4 [[or 5]].

9. (Currently amended): An antibody against a protein according to ~~any one of claims 1 to 3~~ claim 1 or 2 and/or a salt thereof.

10. (Original): A pharmaceutical agent containing an antibody according to claim 9.

11. (Currently amended): A method for producing a protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2, comprising the steps of culturing [[the]] a transformant ~~of claim 8 and producing the protein~~ transformed with a polynucleotide encoding the amino acid sequence.

12. (Currently amended): A method for producing a protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2, characterized by using a cell-free protein synthesis system.

13. (Currently amended): A method for screening a substance interacting with a protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2 and/or a naturally existing protein or a salt thereof containing an amino acid sequence of a protein according to ~~any one of claims 1 to 3~~ claim 1 or 2, comprising the steps of bringing a candidate substance into contact with the protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2; and confirming whether the candidate substance interacts with the protein or a salt thereof.

14. (Currently amended): A method for assaying a protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2 using an antibody ~~of claim 9~~ against said protein or salt thereof.

15. (Currently amended): A method for screening a substance interacting with a protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2, using an ~~assay method of claim 14~~ antibody against said protein or salt thereof.

16. (Currently amended): A method for specifying a gene associated with a protein according to ~~any one of claims 1 to 3~~ claim 1 or 2, comprising the steps of expressing the protein according to ~~any one of claims 1 to 3~~ claim 1 or 2 in a cell; and examining an expression status of the gene in the cell.

17. (Currently amended): A method for screening a compound interacting with a protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2 and/or a naturally existing protein or a salt thereof containing an amino acid sequence of a protein according to ~~any one of claims 1 to 3~~ claim 1 or 2, comprising steps of determining an active site of the protein using information concerning a three-dimensional structure of the protein according to ~~any one of claims 1 to 3~~ claim 1 or 2; and searching a compound interacting with the active site on a computer.

18. (Original): The screening method according to claim 17, wherein the information concerning a three-dimensional structure of the protein is three-dimensional structure information of a protein comprising amino acid residues from amino acid 8 to amino acid 126 among three-dimensional structure information described in any one of three-dimensional structure coordinate tables 1 to 20.

19. (Original): The screening method according to claim 17, wherein, among three-dimensional structure information described in three-dimensional structure coordinate table 1, a part of information corresponding to amino acid residues of ASN15, ASN17, PHE18, THR19, LEU67, ARG70, SER71, VAL72, SER73, ASN74, HIS78, GLY80, ASP82, ASP119, SER122, ASP126, SER127 is used.

20. (Currently amended): A method for screening a substance interacting with a protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2 and/or a naturally existing protein or a salt thereof containing an amino acid sequence of a protein according to ~~any one of claims 1 to 3~~ claim 1 or 2, comprising the steps of preparing specified compound interacting with the active site as a candidate substance by a screening ~~method according to any one of claims 17 to 19~~, and bringing the candidate substance into contact with a protein or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1 or 2; and confirming whether the candidate substance has interaction with the protein or a salt thereof.

21. (Currently amended): A method for presuming a three-dimensional structure of a protein with an unknown structure, wherein homology modeling is conducted on the protein with an unknown structure comprising an amino acid sequence having 30% or more homology with an amino acid sequence of a protein according to ~~any one of claims 1 to 3~~ claim 1 or 2, by using information concerning three-dimensional structure information of a protein having amino acid residues from amino acid 8 to amino acid 126 among three-dimensional structures of a protein described in any one of three-dimensional structure coordinate tables 1 to 20.

22. (Currently amended): A compound inhibiting cellular proliferation activity, characterized in that the compound is obtained by a method according to ~~any one of claims 13, 15, and 17 to 20~~ claim 13.

23. (Original): A cellular proliferation activity inhibitor comprising, as an active ingredient, at least one compound selected from the group consisting of the following compounds i):

i) Compounds represented by items (a) to (e), or a salt thereof:

(a) N-(1,3,5-trimethyl-1H-pyrazol-4-ylmethyl)-7-trifluoromethyl-5,6-dihydro-7a,8,11-triazacyclopenta[b]phenanthrene-9-carboxamide represented by the following structural formula (I):



(I),

(b) 1-[3-[4-(10,11-dihydro-dibenzo[b,f]thiepin-10-yl) piperazin-1-yl]propyl]-1,3-dihydrobenzimidazol-2-one represented by the following structural formula (II):



(II),

(c) 2-(3,4-dimethylphenyl)-2-oxoethyl-2-(3,5-dioxo-4-aza-dibenzo [8,9,10,11]tricyclo[5,2,2,$0^{2,6}$]undecan-4-yl)acetate represented by the following structural formula (III):



(III),

(d) 2-[4-ethyl-5-(4-methylphenylamino)methyl-4H-[1,2,4]triazol-3-yl] sulfanyl-1-(phenothiazin-10-yl)-1-ethanone represented by the following structural formula (IV):




(IV), or

(e) 1-(8-chloro-3-fluoro-10,11-dihydro-dibenzo[b,f]thiepin-10-yl)-4-[2-(1,3-dioxolan-2-yl)ethyl] piperazine represented by the following structural formula (V):




(V)

24. (Original): The cellular proliferation activity inhibitor according to claim 23 for inhibiting proliferation activity of a cancer cell derived from an ovarian cancer cell.

25. (Currently amended): A method for producing a pharmaceutical composition containing a compound of inhibiting a cellular proliferation activity, characterized in that the method comprises a step of blending a compound obtained by a method according to ~~any one of claims 13, 15, and 17 to 20~~ claim 13 with a pharmaceutically acceptable carrier.